姜妮 , 乔国梁 , 王小利 , 周心娜 , 周蕾 , 宋雨光 , 赵艳杰 , 任军 . 中性粒细胞与淋巴细胞比例对评估接受过继性细胞免疫治疗的晚期胰腺癌患者预后的临床意义[J]. 北京大学学报（医学版）, 2020 , 52(3) : 597 -602 . DOI: 10.19723/j.issn.1671-167X.2020.03.031
| [1] | Del Chiaro M, Segersvard R, Lohr M, et al. Early detection and prevention of pancreatic cancer: is it really possible today?[J]. World J Gastroenterol, 2014,20(34):12118-12131. |
| [2] | Yabar CS, Winter JM. Pancreatic cancer: A review[J]. Gas-troenterol Clin North Am, 2016,45(3):429-445. |
| [3] | Zhang Y, Zhang X, Zhang A, et al. Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis[J]. Onco Targets Ther, 2017,10:4173-4192. |
| [4] | Lin M, Liang S, Jiang F, et al. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage Ⅳ breast cancer[J]. Immunol Lett, 2017,183(3):37-43. |
| [5] | Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J]. Oncology, 2000,58(3):191-197. |
| [6] | Hagihara K, Ikeda M, Maeda S, et al. Effectiveness of irinotecan, S-1, and bevacizumab for rectal cancer with lung and skin metastases after adjuvant chemotherapy[J]. Gan To Kagaku Ryoho, 2016,43(12):2313-2315. |
| [7] | Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013,31(13):1640-1648. |
| [8] | Morizane C, Okusaka T, Furuse J, et al. A phase Ⅱ study of S-1 in gemcitabine-refractory metastatic pancreatic cancer[J]. Cancer Chemother Pharmacol, 2009,63(2):313-319. |
| [9] | Jiang N, Qiao G, Wang X-L, et al. Dendritic cell/cytokine induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: A prospective study[J]. Clin Cancer Res, 2017,23(17):5066-5073. |
| [10] | Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy[J]. Curr Opin Oncol, 2013,25(1):50-51. |
| [11] | Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism[J]. Cancer Res, 2000,60(1):184-190. |
| [12] | He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer[J]. Med Oncol, 2013,30(1):439. |
| [13] | Luo G, Liu C, Cheng H, et al. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors[J]. Oncol Lett, 2017,13(4):2454-2458. |
| [14] | Chen Y, Yan H, Wang Y, et al. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma[J]. Sci Rep, 2017,7(1):753. |
| [15] | Formica V, Morelli C, Ferroni P, et al. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin[J]. Cancer Biomark, 2016,17(3):335-345. |
| [16] | Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences[J]. Clin Transl Oncol, 2013,15(10):780-788. |
| [17] | 王艺, 王理伟. 胰腺癌患者免疫状态及免疫治疗进展[J]. 肿瘤, 2018,38(6):610-616. |
| [18] | Meng Y, Yu Z, Wu Y, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application[J]. Hum Vaccin Immunother, 2017,13(6):1-9. |
| [19] | Chen J, Chen Y, Feng F, et al. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer[J]. J Thorac Dis, 2018,10(12):6711-6721. |
| [20] | Wang Q, Liu Y, Chen Y, et al. CD300LG improves the cytotoxic activity of CIK[J]. Cent Eur J Immunol, 2017,42(2):117-122. |
| [21] | Xue P, Kanai M, Mori Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J]. Cancer Med, 2014,3(2):406-415. |
| [22] | Li Y, Wang C, Xu M, et al. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer[J]. J Cancer Res Clin Oncol, 2017,143(5):861-871. |
| [23] | Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor[J]. Angiogenesis, 2003,6(4):283-287. |
| [24] | Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape[J]. Cytokine Growth Factor Rev, 2007,18(1-2):171-182. |
| [25] | Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the evelopment and progression of hepatocarcinogenesis[J]. Clin Cancer Res, 2007,13(3):902-911. |
/
| 〈 |
|
〉 |
